# Weight Loss Surgeries Decline as GLP-1 Use Skyrockets
Bariatric surgeries are losing ground to GLP-1 receptor agonists like semaglutide and tirzepatide as first-line weight loss treatments. The shift reflects how rapidly medical practice evolves when new therapies show strong results with fewer risks.
GLP-1 drugs work by mimicking a hormone that regulates appetite and blood sugar. Patients using semaglutide or tirzepatide typically lose 15 to 22 percent of their body weight over 68 weeks, according to clinical trials. The medications are now prescribed for weight management in people with obesity or overweight with weight-related conditions. Unlike surgery, they carry no operative risk and remain reversible.
Weight loss surgery, including gastric bypass and sleeve gastrectomy, still produces dramatic results. Patients often lose 50 to 70 percent of excess weight long-term. But surgery requires anesthesia, carries infection risks, and causes permanent changes to the digestive system. Recovery takes weeks. Some patients experience nutritional deficiencies requiring lifelong supplementation.
The decline in bariatric procedures reflects access and convenience. GLP-1 medications require only weekly or twice-weekly injections. Patients take them at home. Insurance coverage has expanded significantly since these drugs entered the weight loss market. Bariatric surgery remains limited by surgeon availability, surgical costs, and recovery time.
This doesn't mean surgery is obsolete. Patients with severe obesity and multiple weight-related health conditions sometimes show better outcomes with surgery. Some people lose weight with GLP-1 drugs but regain it after stopping, whereas surgical changes persist. Both approaches have roles in weight management.
The real shift involves patient choice and access. More people can now access effective weight loss treatment without surgery.